Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-27T12:53:12.969Z Has data issue: false hasContentIssue false
  • English
  • Français

New Biochemical Insights to Unravel the Pathogenesis of Alzheimer's Lesions

Published online by Cambridge University Press:  18 September 2015

Alex E. Roher ,
Kenneth C. Palmer ,
John Capodilupo ,
Arun R. Wakade  and
Melvyn J. Ball
Alex E. Roher*
Affiliation:
Department of Anatomy and Cell Biology, Oregon Health Sciences University, Portland
Kenneth C. Palmer
Affiliation:
Department of Pathology, Oregon Health Sciences University, Portland
John Capodilupo
Affiliation:
Department of Anatomy and Cell Biology, Oregon Health Sciences University, Portland
Arun R. Wakade
Affiliation:
Department of Pharmacology, Oregon Health Sciences University, Portland
Melvyn J. Ball
Affiliation:
Wayne State University School of Medicine, Detroi and Division of Neuropathology, Oregon Health Sciences University, Portland
*
Department of Anatomy and Cell Biology, Wayne State University School of Medicine, 540 E. Canfield Ave., Detroi, Michigan, U.S.A. 48201
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Purification of amyloid plaque core proteins (APCP) from Alzheimer's disease brains to complete homogeneity and in high yield permitted its chemical fractionation and characterization of its components. APCP is mainly made of β-amyloid (βA) and an assortment of glycoproteins (accounting for 20%) rich in carbohydrates compatible with N-and O-linked saccharides. When added to tissue culture of sympathetic and sensory neurons APCP and βA inhibited neuritic sprouting, a reversible phenomenon at low doses. Higher concentrations of both substances kill the neurons in culture. APCP is significantly more toxic than βA, suggesting the minor components may play an important role in increasing the toxicity of βA. If the observed toxic effects of APCP in situ are occurring in vivo during the course of AD, then the accumulation of these extracellular proteins could be largely responsible for some of the neuronal death observed in this neuropathology.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue S3 , August 1991 , pp. 408 - 410
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

REFERENCES

1.McGeer, PL, Akiyama, H, Itagaki, S, et al. Immune system response in Alzheimer’s disease. Can J Neurol Sci 1989; 16: 516–527.CrossRefGoogle ScholarPubMed
2.Rogers, J, Luber-Narod, J, Styren, SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging 1988; 9: 339–349.CrossRefGoogle Scholar
3.Gray, EG, Paula-Barbosa, M, Roher, AE. Alzheimer’s disease: paired helical filaments and cytomembranes. Neuropathol Appl Neurobiol 1987; 13:91–110.CrossRefGoogle ScholarPubMed
4.Roher, AE, Palmer, KC, Chau, V, et al. Isolation and chemical characterization of Alzheimer’s disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein. J Cell Biol 1988; 107:2703–2716.CrossRefGoogle ScholarPubMed
5.Kang, J, Lemaire, GG, Unterbeck, A, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell surface receptor. Nature 1987; 325: 733–736.CrossRefGoogle ScholarPubMed
6.Golde, TE, Estus, S, Younkin, LH, et al. PCR amplification of reverse transcribed RNA reveals a fourth alternatively spliced βAPP and mRNA. Soc Neurosci Abstr 1989; 15: 648.Google Scholar
7.Goldgaber, D, Lerman, MI, McBridge, OW, et al. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer’s disease. Science 1987; 235: 877–880.CrossRefGoogle ScholarPubMed
8.Ponte, P, Gonzalez-DeWitt, P, Schilling, J, et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 1988; 331: 525–527.CrossRefGoogle ScholarPubMed
9.Tanzi, RE, McClatchey, Al, Lamperti, ED, et al. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 1988; 331: 528–530.CrossRefGoogle ScholarPubMed
10.Kitaguchi, N, Takahashi, Y, Tokushima, Y, et al. Novel precursor of Alzheimer’s disease amyloid protein shows protease inhibitory activity. Nature 1988; 331: 530–532.CrossRefGoogle ScholarPubMed
11.Oltersdorf, T, Fritz, LC, Schenk, DB, et al. The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is protease nexin II. Nature 1989; 341: 144–147.CrossRefGoogle ScholarPubMed
12.Van Nostrand, WE, Wagner, SL, Suzuki, M, et al. Protease nexin II, a potent antichymotrypsin, shows identity to amyloid P-protein precursor. Nature 1989; 341: 546–549.CrossRefGoogle Scholar
13.Smith, RP, Higuchi, DA, Broze, GJ. Platelet coagulation factor Xlainhibitor, a form of Alzheimer amyloid precursor. Science 1990; 248: 1126–1128.CrossRefGoogle ScholarPubMed
14.Selkoe, DJ, Podlisny, MB, Joachim, CL, et al. Beta amyloid precursor protein of Alzheimer’s disease occurs as 110 to 135 kilodalton membrane associated proteins in neural and non-neural tissues. Proc Natl Acad Sci USA 1988; 85: 7341–7345.CrossRefGoogle Scholar
15.Weidemann, A, Konig, G, Bunke, D, et al. Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 1989; 57: 115–126.CrossRefGoogle ScholarPubMed
16.Miller, DL, Currie, JR, Iqbal, K, et al. Relationships among the cerebral amyloid peptides and their precursors. Ann Med 1989; 21: 83–87.CrossRefGoogle ScholarPubMed
17.Perry, G, Lipphardt, S, Mulvihill, P, et al. Amyloid precursor protein in senile plaques of Alzheimer disease. The Lancet 1988; 2: 746.CrossRefGoogle ScholarPubMed
18.Palmert, MR, Podlisny, M, Witker, DS, et al. Antisera to an aminoterminal peptide detect the amyloid protein precursor of Alzheimer’s disease and recognize senile plaque. Biochem Biophys Res Comm 1988; 156: 432–437.CrossRefGoogle Scholar
19.Szumanska, G, Vorbrodt, AW, Mandybur, TI, et al. Lectin histochemistry of plaques and tangles in Alzheimer’s disease. Acta Neuropathol 1987; 73: 1–11.CrossRefGoogle ScholarPubMed
20.Snow, AD, Willmer, JP, Kisilevsky, R. Sulfated glycosaminoglycans in Alzheimer’s disease. Hum Pathol 1987; 18: 506–510.CrossRefGoogle ScholarPubMed
21.Snow, AD, Wight TN Proteoglycans in the pathogenesis of Alzheimer’s disease and other amyloidosis. Neurobiol Aging 1989; 10:481–497.CrossRefGoogle Scholar
22.Roher, AE, Ball, MJ, Bhave, SN, et al. β-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Bipohys Res Comm 1990; 174: 572–579.CrossRefGoogle Scholar
23.Yankner, BA, Duffy, LK, Kirschner, DA, Neurotrophic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science 1990; 250: 279–282.CrossRefGoogle ScholarPubMed